

Placement completion and secondary trading notice

Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech, is pleased to advise that it has issued 15,833,333 shares at an issue price of \$0.18 together with 7,916,661 attaching options exercisable at \$0.35 expiring on 22 Nov 2025, following the successful completion of a well supported \$3.0m placement (**Placement**). Subject to Shareholder approval, Emyria's Directors will participate in the Placement to the value of \$150,000. (See ASX release 31 Oct 2022).

The Placement received strong demand from new and existing institutional and sophisticated investors, including follow-on investment from Tattarang's Tenmile Ventures and Sixty Two Capital. (See ASX release 22 Nov 2021).

Funds raised will be used to:

- Advance the Phase 3 clinical trial supporting registration and commercialisation activities of EMD-RX5 as an over-the-counter treatment with the TGA
- Support the ongoing development of EMD-RX7, Emyria's high dose CBD
- Advance multiple preclinical screening programs for Emyria's novel MDMA-inspired drug discovery program being developed with the University of Western Australia
- Business development and working capital

The new shares have been issued utilising the Company's existing placement capacity under ASX Listing Rule 7.1A with the options issued under ASX listing rule 7.1.

An Appendix 2A applying for quotation of the shares issued under the Placement has been lodged and a notice under section 708A(5)(e) of the Corporations Act for the secondary trading of the shares issued is attached to this announcement.

- This release has been approved by the Board of Emyria. -

FOR FURTHER INFORMATION

Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com

Andrew Williams
Media Relations
+61 (0) 416 583 672
awilliams@emyria.com

Sufian Ahmad
Corporate Advisor
+61 (0) 412 316 162
info@62capital.com.au

Notice under section 708A(5)(e) of the Corporations Act

Emyria Limited (ASX: EMD) (Issuer), notifies ASX (as the operator of the prescribed financial market on which the securities identified below are or are to be quoted) under section 708A(5)(e) of the Corporations Act that:

1. The securities identified below were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. As at the date of this notice the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and with section 674 of the Corporations Act; and
3. As at the date of this notice, there is no excluded information of the type referred to in subsections 708A(7) and 708A(8) of the Corporations Act.

DETAILS OF THE SECURITIES ISSUED	
Class of Securities:	Ordinary Shares
ASX Code of the Securities:	EMD
Date of the issue of securities:	22 November 2022
Total number of Shares issued:	15,833,333

- This release has been approved by the Board of Emyria. -

DRUG DEVELOPMENT

CLINICAL PROGRAMS
Ultra-Pure cannabinoid delivery platform

NEW DRUG DISCOVERY

PRE-CLINICAL PROGRAM
MDMA-like analogues

EMD-RX5 "direct-to-consumer"	
Formulation optimisation	✓
Phase 1 study	✓
Ethics approved for Phase 3	✓
Phase 3 commencement	✓
Regulatory submission	
Commercial strategy Australia	
Commercial strategy Europe	
Commercial strategy USA	

EMD-RX7 "prescription medicine"	
Formulation optimisation	✓
Phase 1	
Pre-IND (FDA)	
Pivotal trials	

MDMA-like drug development	
Continuous creation & screening	✓
First patent family filed	✓
US-focused preclinical program	✓
Metabolic studies	✓
Preclinical assays (multiple animal models)	✓
Human cell line assays	✓
Advanced assay development	
Lead selection	
Phase 1 trials	
Global commercial strategy	

ABOUT EMYRIA | emyria.com

Emyria Limited is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes in neuroscience and mental health via:

- **Drug Development:** Emyria has developed an Ultra-Pure cannabinoid platform that can support the registration of multiple proprietary dose forms. Emyria's first dose form, EMD-RX5 is in Phase 3 trials
- **New Drug Discovery:** Inspired by MDMA, Emyria is developing one of the world's largest libraries of MDMA-like compounds with partner, the University of Western Australia.
- **Proprietary Real-World Data (RWD):** Emyria gathers ethically-sourced data with patients cared for at Emyria's own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement.

EMYRIA'S

[Investorhub.emyria.com](https://investorhub.emyria.com)

INTERACTIVE

Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

INVESTOR

HUB

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.